Literature DB >> 19508475

Haematodermic CD4+CD56+ neoplasm: complete remission after methotrexate-asparaginase treatment.

J Fontaine1, L Thomas, B Balme, S Ronger-Savle, C Traullé, T Petrella, S Dalle.   

Abstract

Haematodermic neoplasm is a recently recognized condition, characterized by tumour cells expressing CD4, CD56 and CD123. This phenotype is strongly suggestive of a plasmacytoid dendritic cell origin. This haematopoietic malignancy is a distinct clinicopathological condition with frequent skin involvement, an evolution toward leukaemia and a rapidly aggressive course. We report the case of a 64-year-old woman who presented with a haematodermic CD4+CD56+CD123+ neoplasm affecting the left cheek; the initial staging was otherwise negative. Despite this early stage of the disease, aggressive treatment including methotrexate-asparaginase and local radiotherapy was proposed as first-line therapy. Complete clinical remission was rapidly reached and the patient was still alive after > 30 months of follow-up. To date there is no consensus on the first-line treatment for such patients but intensive treatment is probably needed immediately even in cases of localized disease. The response obtained with CHOP (cyclophosphamide, doxyrubicin, vincristine, prednisone) or CHOP-like chemotherapy regimens is disappointing. Other regimens, such as those used in acute leukaemia, may improve the outcome of these patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19508475     DOI: 10.1111/j.1365-2230.2008.03100.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  6 in total

1.  In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent.

Authors:  Fanny Angelot-Delettre; Anne Roggy; Arthur E Frankel; Baptiste Lamarthee; Estelle Seilles; Sabeha Biichle; Bernard Royer; Eric Deconinck; Eric K Rowinsky; Christopher Brooks; Valerie Bardet; Blandine Benet; Hind Bennani; Zehaira Benseddik; Agathe Debliquis; Daniel Lusina; Mikael Roussel; Françoise Solly; Michel Ticchioni; Philippe Saas; Francine Garnache-Ottou
Journal:  Haematologica       Date:  2014-11-07       Impact factor: 9.941

2.  BPDCN: When polychemotherapy does not compromise allogeneic CD123 CAR-T cell cytotoxicity.

Authors:  Margaux Poussard; Laure Philippe; Maxime Fredon; Elodie Bôle-Richard; Sabeha Biichle; Florian Renosi; Sophie Perrin; Marie Kroemer; Samuel Limat; Francis Bonnefoy; Etienne Daguindau; Eric Deconinck; Bérengère Gruson; Philippe Saas; Olivier Adotévi; Francine Garnache-Ottou; Fanny Angelot-Delettre
Journal:  EJHaem       Date:  2020-12-13

3.  Blastic plasmacytoid dendritic cell neoplasm in children: A review of two cases.

Authors:  Wenjun Deng; Minghua Yang; Feimei Kuang; Yingting Liu; Hui Zhang; Lizhi Cao; Min Xie; Liangchun Yang
Journal:  Mol Clin Oncol       Date:  2017-08-08

4.  Radiation therapy for cutaneous blastic plasmacytoid dendritic cell neoplasm: a case report and review of the literature.

Authors:  Naoya Ishibashi; Toshiya Maebayashi; Takuya Aizawa; Masakuni Sakaguchi; Osamu Abe; Katsuhiro Miura; Yoshihiro Hatta; Masahiko Sugitani
Journal:  Int J Clin Exp Med       Date:  2015-05-15

Review 5.  Sustained complete remission of a limited-stage blastic plasmacytoid dendritic cell neoplasm followed by a simultaneous combination of low-dose DeVIC therapy and radiation therapy: a case report and review of the literature.

Authors:  Kei-Ji Sugimoto; Asami Shimada; Nanae Yamaguchi; Hidenori Imai; Mutsumi Wakabayashi; Yasunobu Sekiguchi; Hiroshi Izumi; Yasunori Ota; Norio Komatsu; Masaaki Noguchi
Journal:  Int J Clin Exp Pathol       Date:  2013-10-15

Review 6.  Conventional Therapeutics in BPDCN Patients-Do They Still Have a Place in the Era of Targeted Therapies?

Authors:  Margaux Poussard; Fanny Angelot-Delettre; Eric Deconinck
Journal:  Cancers (Basel)       Date:  2022-08-02       Impact factor: 6.575

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.